Effectiveness of probiotics in reducing the incidence of Clostridium difficile-associated diarrhea in elderly patients: A systematic review

JBI Database of Systematic Reviews and Implementation Reports

Volumn 15, Issue 1, 2017, Pages 140-164

  Vernaya, Marina ^a,b   McAdam, Jennifer ^a,b   Hampton, Michelle DeCoux ^a,b  

^a SAMUEL MERRITT UNIVERSITY   (United States)

^b Joanna Briggs Institute Center of Excellence   (United States)

Author keywords

Clostridium difficile; Diarrhea; Elderly; Probiotics; Toxin

Indexed keywords

ANTIBIOTIC AGENT; PLACEBO; PROBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; CLOSTRIDIUM DIFFICILE INFECTION; DRUG EFFICACY; GERIATRIC PATIENT; HOSPITAL PATIENT; HUMAN; OUTCOME ASSESSMENT; REVIEW; SYSTEMATIC REVIEW; AGED; DIARRHEA; INCIDENCE; ISOLATION AND PURIFICATION; MICROBIOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

AGED; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; DIARRHEA; HUMANS; INCIDENCE; PROBIOTICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85018468803     PISSN: None     EISSN: 22024433     Source Type: Journal    
DOI: 10.11124/JBISRIR-2016-003234     Document Type: Review

References (57)

1. American Association of Immunologists. Nobel laureates of AAI: Sir Alexander Fleming, F.R.C.S. (1881-1955). 2014; [Internet] [cited Sep 22, 2014]. Available from: http://www.aai.org/About/History/Notable-Members/pdfs/Nobel/AAI-Fleming-Alexander.pdf.
2. American Academy of Pediatrics. The history of antibiotics. 2014; [Internet] [cited Sep 23, 2014]. Available from: http://www.healthychildren.org/English/health-issues/conditiions/treatments/pages/The-History-of-Antibiotics.aspx.
3. Centers for Disease Control and Prevention. Core elements of hospital antibiotic stewardship programs. 2014; [Internet] [cited Sep 22, 2014]. Available from: http://stacks.cdc.gov/view/cdc/25302.
4. Centers for Disease Control and Prevention. Frequently asked questions about Clostridium difficile for healthcare providers. 2012; [Cited Sep 22, 2014]. Available from: http://www.cdc.gov/HAI/organisms/cdiff/Cdiff-faqs-HCP.html.
5. Lim CJ, Kong DC, Stuart RL. Reducing inappropriate antibiotic prescribing in the residential care setting: current perspectives. Clin Interv Aging 2014; 9:165-77.
6. Cecil JA Clostridium difficile: changing epidemiology, treatment and infection prevention measures. Curr Infect Dis Rep 2012; 14(6):612-9.
7. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States. 2013; [Internet] [cited on Sep 20, 2014]. Available from: http://www.cdc.gov/drugresistance/threat-report-2013/pdf/arthreats-2013-508.pdf.2013.
8. Centers for Disease Control and Prevention. Vital Signs. 2012; [Internet] [cited on Sep 23, 2014]. Available from: http://www.cdc.gov/VitalSigns/Hai/StoppingCdifficile/.
9. California Department of Public Health. Brief report: healthcare-associated Clostridium difficile infections in California hospitals, January 2009 through March 2010-2010; [Cited March, 2010]. Available from: http://www.cdph.ca/gov/programs/hai/Documents/HAIReportSB-1058Cdiff-FINAL.pdf.
10. Crogan NL, Evans BS. Clostridium difficile: an emerging epidemic in nursing homes. Geriatr Nurs 2007; 28(3):161-4.
11. Simor AE, Bradley SF, Strausbaugh LJ, Crossley K, Nicolle LE. Clostridium difficile in long-term-care facilities for the elderly. Infect Cont Hosp Epidemiol 2002; 23(11):696-703; [Internet] [cited February, 2015]. Available from: http://www.shea-online/org/Assets/files/position-papers/SHEA-Cdiff.pdf.
12. Feldman M, Cryer B, McArthur KE, Huet BA, Lee E. Effects of aging and gastritis on gastric acid and pepsin secretion in humans: a prospective study. Gastroenterology 1996; 110(4):1043-52.
13. Vedantam G, Clark A, Chu M, McQuade R, Mallozzi M, Viswanathan VK. Clostridium difficile infection: toxins and non-toxin virulence factors, and their contributions to disease establishment and host response. Gut Microbes 2012; 3(2):121-34.
14. Lyras D, O'Connor JR, Howarth PM, Sambol SP, Carter GP, Phumoonna T, et al. Toxin B is essential for virulence of Clostridium difficile. Nature 2009; 458(7242):1176-9.
15. Redelings MD, Sorvillo F, Mascola L. Increase in Clostridium difficile-related mortality rates, Unites States 1999-2004. Emerg Infect Diseases 2007; 13(9):1418-9.
16. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Disease Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31(5):431-55.
17. Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013; 108:478-98.
18. Gao XW, Mubasher M, Fang CY, Reifer C, Miller LE. Doseresponse efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285oR for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol 2010; 105(7): 1636-1641.
19. Hickson M, D'Souza A, Muthu N, Rogers TR, Want S, Rajkumar C, et al. Use of probiotics Lactobacillus preparation to prevent diarrhea associated with antibiotics: Randomized double blind placebo controlled trial. BMJ 2007; 335(7610):1-5.
20. Klarin B, Wullt M, Palmquist I, Molin G, Larsson A, Jeppsson B. Lactobacillus plantarum 299 v reduces colonization of Clostridium difficile in critically ill patients treated with antibiotics. Acta Anaesthesiol Scand 2008; 52(18):1096-102.
21. Lahtinen SJ, Forssten S, Aakko J, Granlund L, Rautonen N, Salminen S, et al. Probiotic cheese containing lactobacillus rhamnosus HN001 and Lactobacillus acidophilus NCFM modifies subpopulations of fecal lactobacilli and Clostridium difficile in the elderly. Age 2011; 34(1):133-43.
22. Ouwehand AC, DongLian C, Weijian X, Stewart M, Ni J, Stewart T, et al. Probiotics reduce symptoms of antibiotic use in a hospital setting: a randomized dose response study. Vaccine 2014; 32(4):458-63.
23. Plummer S, Weaver MA, Harries JC, Dee P, Hunter J. Clostridium difficile pilot study: effects of probiotics supplementation on the incidence of C. difficile diarrhoea. Int Microbiol 2004; 7(1):59-62.
24. Chatterjee S, Kar P, Das T, Ray S, Ganguly S, Rajendiran C, et al. Randomized placebo-controlled double blind multicenter trial on efficacy and safety of Lactobacillus acidophilus LA-5 and Bifidobacterium BB-12 for prevention of antibiotic-associated diarrhoea. J Assoc Phys India 2013; 61:708-12; [Internet].
25. Goldenberg JZ, Ma SSY, Saxton JD, Martzen MR, Vandvik PO, Thorlund K, et al. Probiotic for the prevention of Clostridium difficile-associated diarrhea in adults and children (Review). Cochrane Database Syst Rev; 2013(5):CD006095; [Internet].
26. Nelson PA Probiotics for treatment of Clostridium difficile-associated colitis in adults (Review). Cochrane Database Syst Rev (1):2008:CD004611.
27. Vernaya M, McAdam J. The effectiveness of probiotics in reducing the incidence of Clostridium difficile associated diarrhea in elderly patients: a systematic review protocol. JBI Database System Rev Implement Rep 2015; 13(8):79-91.
28. Naik P, Marshall B. Focus: probiotics for prevention and adjunctive therapy. APUA newsletter. 2012; [Internet] [cited May 1, 2015]. Available from http://www.tufts.edu/med/apua/news/newsletter-29-1655861331.pdf.
29. Review Manager (RevMan) [Computer program]. Version 5.3. The Nordic Cochrane Centre. Copenhagen: The Cochrane Collaboration; 2014.
30. Lewis SJ, Potts LF, Barry RE. The lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibioticrelated diarrhoea in elderly patients. J Infect 1998; 36(2):171-4.
31. Pozzoni P, Riva A, Bellatorre AG, Amigoni M, Redaelli E, Ronchetti A, et al. Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: a single-center, randomized, double-blind, placebo-controlled trial. Am J Gastroenterol 2012; 107(6):922-31.
32. Allen SJ, Wareham K, Wang D, Bradley C, Hutchings H, Harris W, et al. Lactobacilli and bifidobacteria in the prevention of antibiotic-aspozzonisociated diarrhoea and Clostridium difficle diarhoea in older inpatients (PLACIDE): a randomized, double-blind, placebo-controlled, multicenter trial. Lancet 2013; 382(9900):1249-57.
33. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21(11):1539-58.
34. Kamhuber C, Hörist-Kollmann S, Rek A, Eckhardt G, Zauner A, Gabriel P. Preventing antibiotic associated diarrhoea using a probiotic Lactobacillus Casei preparation. Z Gastroenterol [Abstract] 2009; 47(1).
35. Flatley EA, Wilde AM, Nailor MD. Saccharomyces boulardii for the prevention of hospital onset Clostridium difficile infection. J Gastrointestin Liver Dis 2015; 24(1):21-4.
36. Bakken JS Resolution of recurrent Clostridium difficileassociated diarrhea using staggered antibiotic withdrawal and kefir. Minn Med 2009; 92(7):38-40.
37. Bakken JS Staggered and tapered antibiotic withdrawal with administration of kefir for recurrent Clostridium difficile infection. Clin Infect Dis 2014; 59(6):858-61.
38. Kimmey MB, Elmer GW, Surawicz CM, McFarland LV. Prevention of further recurrences of Clostridum difficile colitis with Saccharomyces boulardii. Dig Dis Sci 1990; 35(7):897-901.
39. Lewis S, Burmeister S, Brazier J. Effect of the probiotic oligofrucotse on relapse of Clostridium difficile-associated diarrhea: a randomized, controlled study. Clin Gastroenterol Hepatol 2005; 3(5):442-8.
40. Surawicz CM, McFarland LV, Greenberg RN, Rubin M, Fekety R, Mulligan ME, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose of vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000; 31(4):1012-7.
41. Wullt M, Hagslätt MLJ, Odenholt I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium diffiicleassociated diarrhoea: a double-blind, placebo-controlled trial. Scand J Infect Dis 2003; 35(6-7):365-7.
42. Lönnermark E, Friman V, Lappas G, Sandberg T, Berggren A, Adlerberth I. Intake of lactobacillus plantarum reduces certain gastrointestinal symptoms during treatment with antibiotics. J Clin Gastroenterol 2010; 44(2): 106-12.
43. McFarland LV, Surawicz CM, Greenberg RN, Fekety R, Elmer GW, Moyer KA, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clsotridium difficile. JAMA 1994; 271(24): 1913-8.
44. McFarland LV, Surawicz M, Greenberg RN, Elmer GW, Moyer KA, Melcher SA, et al. Prevention of β-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol 1995; 90(3):439-48.
45. Morrow LE, Kollef MH, Casale TB. Probiotic prophylaxis of ventilator-associated pneumonia. Am J Respir Crit Care Med 2010; 182(8):1058-64.
46. Selinger CP, Bell A, Cairns A, Lockett M, Sebastian S, Haslam N. Probiotic VSL#3 prevents antibiotic-associated diarrhoea in a double-blind, randomized, placebo-controlled clinical trial. J Hosp Infect 2013; 84(2):159-65.
47. Sullivan A, Johansson A, Svenungsson B, Nord CE. Effect of Lactobacillus F19 on the emergence of antibiotic-resistant microorganisms in the intestinal microflora. J Antimicrob Chemother 2004; 54(4):791-7.
48. Thomas MR, Litin SC, Osmon DR, Corr AP, Weaver AL, Lohse CM. Lack of effect of Lactobacillus GG on antibiotic-associated diarrhea: a randomized, placebo-controlled trial. Mayo Clin Proc 2001; 76(9):883-9.
49. Vonberg RP, Reichardt C, Behnke M, Schwab F, Zindler S, Gastmeier P. Costs of nosocomial Clostridium difficile-associated diarrhoea. J Hosp Infect 2008; 70(1):15-20.
50. Walton GE, van den Heuvel EGHM, Kosters MHW, Rastall RA, Tuohy KM, Gibson GR. A randomized crossover study investigating the effects of galacto-oligosaccharides on the faecal microbiota in men and women over 50 years of age. Br J Nutr 2012; 107(10): 1466-1475.
51. Wenus C, Goll R, Loken EB, Biong AS, Halvorsen DS, Florholmen J. Prevention of antibiotic-associated diarrhoea by a fermented probiotic milk drink. Eur J Clin Nutr 2008; 62(2):299-301.
52. Beniwal RS, Arena VC, Thomas L, Narla S, Imperiale TF, Chaudhry RA, et al. A randomized trial of yogurt for prevention of antibiotic-associated diarrhea. Dig Dis Sci 2003; 40(10):2077-82.
53. Wullt M, Hagslätt MLJ, Odenholt I, Berggren A. Lactobacillus plantarum 299v enhances the concentrations of fecal shortchain fatty acids in patients with recurrent Clostridium difficile-associated diarrhea. Dig Dis Sci 2007; 52:2082-6.
54. StatsDirect Limited. Heterogeneity in meta-analysis. England: StatsDirect; 2000-2016; [Internet] [cited August 5, 2016]. Available from: http://www.statsdirect.com/help/default.htm#meta-analysis/heterogeneity.htm.
55. Frohmander TJ, Chaboyer WP, Robertson IK, Gowardman J. Decrease in frequency of liquid stool in enterally fed critically ill patients given the multispecies probiotic VSL#3: a pilot trial. Am J Crit Care 2010; 19(3):e1-1.
56. Benerjee P, Merkel GJ, Bhunia AK. Lactobacillus delbrueckii ssp. bulgaricus B-30892 can inhibit cytotoxic effects and adhesion of pathogenic Clostridium difficile to Caco-2 cells. Gut Pathog 2009; 1(8):1-11.
57. Zaharoni H, Rimon E, Vardi H, Friger M, Bolotin A, Sharhar DR. Probiotics improve bowel movements in hospitalized elderly patients - the proage study. J Nutr Health Aging 2011; 15(3):215-20; [Internet].